Статья

Healthcare disparities among anticoagulation therapies for severe COVID-19 patients in the multi-site VIRUS registry

C. Kirkup, C. Pawlowski, A. Puranik, I. Conrad, J. O'Horo, D. Gomaa, V. Banner-Goodspeed, J. Mosier, I. Zabolotskikh, S. Daugherty, M. Bernstein, H. Zaren, V. Bansal, B. Pickering, A. Badley, R. Kashyap, A. Venkatakrishnan, V. Soundararajan,
2021

Here we analyze hospitalized andintensive care unit coronavirus disease 2019 (COVID-19) patient outcomes from the international VIRUS registry (https://clinicaltrials.gov/ct2/show/NCT04323787). We find that COVID-19 patients administered unfractionated heparin but not enoxaparin have a higher mortality-rate (390 of 1012 = 39%) compared to patients administered enoxaparin but not unfractionated heparin (270 of 1939 = 14%), presenting a risk ratio of 2.79 (95% confidence interval [CI]: [2.42, 3.16]; p = 4.45e−52). This difference persists even after balancing on a number of covariates including demographics, comorbidities, admission diagnoses, and method of oxygenation, with an increased mortality rate on discharge from the hospital of 37% (268 of 733) for unfractionated heparin versus 22% (154 of 711) for enoxaparin, presenting a risk ratio of 1.69 (95% CI: [1.42, 2.00]; p = 1.5e−8). In these balanced cohorts, a number of complications occurred at an elevated rate for patients administered unfractionated heparin compared to patients administered enoxaparin, including acute kidney injury, acute cardiac injury, septic shock, and anemia. Furthermore, a higher percentage of Black/African American COVID patients (414 of 1294 [32%]) were noted to receive unfractionated heparin compared to White/Caucasian COVID patients (671 of 2644 [25%]), risk ratio 1.26 (95% CI: [1.14, 1.40]; p = 7.5e−5). After balancing upon available clinical covariates, this difference in anticoagulant use remained statistically significant (311 of 1047 [30%] for Black/African American vs. 263 of 1047 [25%] for White/Caucasian, p =.02, risk ratio 1.18; 95% CI: [1.03, 1.36]). While retrospective studies cannot suggest any causality, these findings motivate the need for follow-up prospective research into the observed racial disparity in anticoagulant use and outcomes for severe COVID-19 patients.

Цитирование

Похожие публикации

Источник

Версии

  • 1. Version of Record от 2021-01-01

Метаданные

Об авторах
  • C. Kirkup
    nference
  • C. Pawlowski
    nference
  • A. Puranik
    nference
  • I. Conrad
    nference
  • J. O'Horo
    Mayo Clinic
  • D. Gomaa
    University of Cincinnati
  • V. Banner-Goodspeed
    Beth Israel Deaconess Medical Center
  • J. Mosier
    Banner - University Medical Center Tucson
  • I. Zabolotskikh
    Kuban State Medical Academy
  • S. Daugherty
    Cox Medical Center
  • M. Bernstein
    Stamford Health
  • H. Zaren
    St. Joseph's/Candler Health System
  • V. Bansal
    Mayo Clinic
  • B. Pickering
    Mayo Clinic
  • A. Badley
    Mayo Clinic
  • R. Kashyap
    Mayo Clinic
  • A. Venkatakrishnan
    nference
  • V. Soundararajan
    nference
Название журнала
  • Journal of Medical Virology
Номер гранта
  • undefined
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC BY
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus